{"id":"placebo-for-estradiol-gel","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1511","moleculeType":"Small molecule","molecularWeight":"356.51"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Placebo for estradiol gel","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T06:53:10.056251+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T06:53:16.419646+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Placebo for estradiol gel","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T06:53:17.373202+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Estrogen receptor alpha agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T06:53:18.673016+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1511/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T06:53:18.570524+00:00"}},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebos are inert formulations used as controls in clinical trials to establish the efficacy of active drugs by comparison. In this case, it is a gel formulation designed to match the appearance and administration route of estradiol gel but without any hormonal activity. Any observed effects are attributable to the placebo effect or natural disease progression rather than direct pharmacological action.","oneSentence":"A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:50.719Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T06:53:20.388048+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Control arm in clinical trials for estradiol gel formulations"}]},"trialDetails":[{"nctId":"NCT05317364","phase":"PHASE4","title":"Topical Vaginal Estrogen for Postpartum Obstetric Anal Sphincter Injury Recovery","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2022-07-14","conditions":"Obstetric; Injury Pelvic Floor, Sexual Dysfunction, Anal Incontinence","enrollment":38},{"nctId":"NCT06253702","phase":"PHASE4","title":"Brain Blood Flow Responses to Stress: Sex Differences","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2024-07-24","conditions":"Cerebrovascular Disorders","enrollment":22},{"nctId":"NCT06856174","phase":"PHASE4","title":"Menopausal HT for Women Living With HIV (HoT)","status":"NOT_YET_RECRUITING","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2026-01-19","conditions":"HIV Infection, Menopause","enrollment":105},{"nctId":"NCT05982470","phase":"PHASE2","title":"Effect of Menopause Hormone Therapy In Postmenopausal Women With CSVD And MCI","status":"UNKNOWN","sponsor":"Beijing Tiantan Hospital","startDate":"2023-08-18","conditions":"Cerebral Small Vessel Diseases, Postmenopausal Symptoms, Mild Cognitive Impairment","enrollment":328},{"nctId":"NCT00694733","phase":"NA","title":"Regulation of Cortisol Metabolism and Fat Patterning","status":"UNKNOWN","sponsor":"Oregon Health and Science University","startDate":"2005-05","conditions":"Obesity, Menopausal Syndrome","enrollment":140},{"nctId":"NCT00160173","phase":"PHASE4","title":"Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy","status":"COMPLETED","sponsor":"ASCEND Therapeutics","startDate":"2004-12-02","conditions":"Postmenopausal Symptoms","enrollment":221},{"nctId":"NCT02349386","phase":"PHASE2","title":"Maintaining Suppression of Testosterone With Transdermal Estradiol Gel","status":"TERMINATED","sponsor":"BHR Pharma, LLC","startDate":"2015-07","conditions":"Cancer of the Prostate","enrollment":34},{"nctId":"NCT04574999","phase":"PHASE3","title":"Study to Determine Efficacy & Safety of a Low Concentration Estriol (0.005%) in Postmenopausal Vaginal Atrophy.","status":"COMPLETED","sponsor":"Italfarmaco S.A","startDate":"2008-01-25","conditions":"Vaginal Atrophy","enrollment":167},{"nctId":"NCT04330677","phase":"PHASE1","title":"Dissecting the Role of Estradiol in Mediating Gender-specific Anxiolytic and Prosocial Effects of Oxytocin","status":"COMPLETED","sponsor":"University Hospital, Bonn","startDate":"2016-09-18","conditions":"Oxytocin, Estrogen, Fear Extinction","enrollment":487},{"nctId":"NCT02967510","phase":"PHASE2","title":"Study Evaluating the Efficacy and Safety of Three Formulations of Ultra-low Dose Estriol Vaginal Gel (0.005%, 0.002%, 0.0008% Estriol Vaginal Gel) for the Treatment of Vaginal Dryness in Postmenopausal Women With Vulvovaginal Atrophy","status":"COMPLETED","sponsor":"ITF Research Pharma, S.L.U.","startDate":"2016-10","conditions":"Vaginal Atrophy","enrollment":283},{"nctId":"NCT02516202","phase":"PHASE3","title":"The Vaginal Health Trial","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2016-04","conditions":"Atrophy of Vagina, Menopause, Dyspareunia (Female)","enrollment":302},{"nctId":"NCT01686828","phase":"PHASE1, PHASE2","title":"T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin","status":"COMPLETED","sponsor":"University of Washington","startDate":"2013-06","conditions":"Insulin Resistance, Type 2 Diabetes Mellitus, Obesity","enrollment":53},{"nctId":"NCT00668603","phase":"NA","title":"Comparison of Vascular Findings Between Symptomatic and Asymptomatic Postmenopausal Women Before and During Hormone Therapy (HRT)","status":"COMPLETED","sponsor":"University of Helsinki","startDate":"2005-08","conditions":"Postmenopausal Vasomotor Symptoms, Cardiovascular Disease","enrollment":160},{"nctId":"NCT01613131","phase":"NA","title":"Mirena and Estrogen for Control of Perimenopause Symptoms and Ovulation Suppression","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2012-04","conditions":"Menopausal and Other Perimenopausal Disorders","enrollment":39},{"nctId":"NCT02316249","phase":"PHASE2","title":"Vaginal Creams to Reduce Vaginal Erosion in Pessary Users","status":"WITHDRAWN","sponsor":"Northwell Health","startDate":"2015-04","conditions":"Atrophy of Vagina, Vaginal Ulceration, Vaginitis","enrollment":""},{"nctId":"NCT00729859","phase":"PHASE2","title":"CEP-1 Hormonal Regulation of Circulating Endothelial Progenitor Cells and HDL-C in Men","status":"COMPLETED","sponsor":"University of Washington","startDate":"2008-12","conditions":"Healthy","enrollment":31},{"nctId":"NCT00391417","phase":"PHASE3","title":"Efficacy and Safety of a Topical Estradiol Gel for Treatment of Postmenopausal Symptoms","status":"COMPLETED","sponsor":"BioSante Pharmaceuticals","startDate":"2003-09","conditions":"Hot Flashes","enrollment":431}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL1511"},"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo for estradiol gel","genericName":"Placebo for estradiol gel","companyName":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","companyId":"advancing-clinical-therapeutics-globally-for-hiv-aids-and-other-infections","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect. Used for Control arm in clinical trials for estradiol gel formulations.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T06:53:20.388048+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}